Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Foods International CoPMDSF 69 3-Year EBITDA Growth Rate is 19.70% as of Jan. 2026, which is 69% below its 10-year median of 64.30. GuruFocus rates PMDSF with a GF Score™ of 69/100 and a GF Value™ of $10.87. The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, Pharma Foods International Co ranks better than 67.24% on this metric.
During the past 12 months, Pharma Foods International Co's average EBITDA Per Share Growth Rate was -139.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pharma Foods International Co was 151.80% per year. The lowest was -42.20% per year. And the median was 64.30% per year.
Pharma Foods International Co (OTCPK:PMDSF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pharma Foods International Co 3-Year EBITDA Growth Rate Related Terms
PMDSF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharma Foods International Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Foods International Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharma Foods International Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pharma Foods International Co's 3-Year EBITDA Growth Rate falls into.
Pharma Foods International Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.70% mean?
Pharma Foods International Co (PMDSF) has a 3-Year EBITDA Growth Rate of 19.70% as of Jan. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharma Foods International Co and its competitors. This is 69% below median its historical median of 64.30. According to the industry distribution chart, Pharma Foods International Co ranks #265 out of 809 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Pharma Foods International Co's 3-Year EBITDA Growth Rate too high?
Pharma Foods International Co's current 3-Year EBITDA Growth Rate of 19.70% is 69% below median its 10-year median of 64.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Pharma Foods International Co's value of 19.70% is 121.3% above this industry median. Based on the distribution chart, Pharma Foods International Co ranks #265 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pharma Foods International Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Pharma Foods International Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Pharma Foods International Co ranks #265 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Pharma Foods International Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Pharma Foods International Co's value of 19.70% is 121.3% above this benchmark. While the company's 10-year median is 64.30 vs. the industry median of 8.90, Pharma Foods International Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Foods International Co's current 3-Year EBITDA Growth Rate of 19.70% is 121.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharma Foods International Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Foods International Co's current 3-Year EBITDA Growth Rate is 19.70%, which is 69% below median its own 10-year median of 64.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Foods International Co stock overvalued right now?
Pharma Foods International Co (PMDSF) has a current 3-Year EBITDA Growth Rate of 19.70%. The stock's GF Value™ is $10.87, compared to a current price of $6.40 — trading 41.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.70%, which is 69% below median its 10-year median of 64.30 and 121.3% above the Drug Manufacturers industry median of 8.90. Pharma Foods International Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pharma Foods International Co (PMDSF), the current 3-Year EBITDA Growth Rate is 19.70% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Foods International Co (PMDSF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Foods International Co stock appears to be undervalued.
The current stock price of $6.40 is trading 41.1% below its estimated GF Value™ of $10.87.
Key valuation signals for PMDSF:
3-Year EBITDA Growth Rate: 19.70% (69% below median its 10-year median of 64.30)
GF Value™: $10.87 vs. price of $6.40 (41.1% below fair value)
Industry Position: 121.3% above the Drug Manufacturers median (#265 of 809)
No single metric tells the full story. See the PMDSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDSF has been successfully added to your 
